Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (132)

2024

  1. A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

    Clinical Cancer Research, Vol. 30, Núm. 4, pp. 695-702

  2. CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  3. Gastric neuroendocrine neoplasms

    Nature Reviews Disease Primers, Vol. 10, Núm. 1

  4. Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 62-74

  5. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

    Nature Communications, Vol. 15, Núm. 1

  6. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871

  7. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

    Future Oncology, Vol. 20, Núm. 20, pp. 1401-1413

  8. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651

2023

  1. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA

    Genome Medicine, Vol. 15, Núm. 1

  2. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

    Endocrine reviews, Vol. 44, Núm. 4, pp. 724-736

  3. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  4. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours

    Journal of Neuroendocrinology, Vol. 35, Núm. 6

  5. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  6. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

    Journal of Clinical Oncology

  7. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194

  8. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388

  9. Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes

    Journal of Molecular Pathology, Vol. 4, Núm. 3, pp. 128-155

  10. MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms

    Molecular Oncology, Vol. 17, Núm. 4, pp. 582-597

  11. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

    Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036

  12. SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2692-2706